Michael Shank, DO
Family Medicine · Colorado Springs, CONPI 1720056336
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $878 of the $1,403 with a category attached, or 62.6%. 18 manufacturers reported payments, led by AstraZeneca at 59.6% of the total. Reporting peaked in 2021 at $941 and has fallen 95.6% since, to $41 in 2023.
Across 34 payments — averaging $41.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$837
- Novo Nordisk$121
- Hologic Sales And Service, LLC$61
- Acorda Therapeutics, Inc$53
- Medtronic$33
- Pfizer$33
- plus $265 from 12 others
What the payments were for
- Speaking & faculty fees$87863%
- Food & beverage$52537%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 2 | $837 |
| Novo Nordisk | 7 | $121 |
| Hologic Sales And Service, LLC | 3 | $61 |
| Acorda Therapeutics, Inc | 2 | $53 |
| Medtronic(2 entities) | 2 | $33 |
| Pfizer | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Johnson & Johnson | 2 | $30 |
| AbbVie | 1 | $29 |
| Astellas Pharma US Inc | 2 | $27 |
| Acadia Pharmaceuticals Inc | 2 | $24 |
| Boston Scientific | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Amgen | 1 | $19 |
| Novartis | 1 | $19 |
| Strongbridge US Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Nevro Corp. | 1 | $11 |
How this compares
$1,403 in reported general payments places this provider in the 80th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $64,186 |
| MyrbetriqMirabegron | 12 | $16,114 |
| Levothyroxine Sodium | 128 | $2,146 |
| Gabapentin | 61 | $1,964 |
| Atorvastatin Calcium | 95 | $1,674 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 18 | $1,596 |
| Omeprazole | 67 | $1,474 |
| Losartan Potassium | 54 | $1,409 |
| Tamsulosin Hcl | 41 | $1,383 |
| Metoprolol Succinate | 64 | $1,307 |
| Amlodipine Besylate | 90 | $1,230 |
| Donepezil Hcl | 79 | $1,112 |
| Buspirone Hcl | 63 | $1,058 |
| Trazodone Hcl | 57 | $880 |
| Tramadol Hcl | 45 | $808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $33 | $64,18676 claims |
| Astellas Pharma US IncMyrbetriq | $27 | $16,11412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Colorado Springs
- Matthew YoungColorado Springs$270K
- Lawrence AndrewsColorado Springs$102K
- Elizabeth EricksonColorado Springs$31K
- Daniel RohwederColorado Springs$21K
- Gary TarshisColorado Springs$10K
- Jeremy BrownColorado Springs$8K
- Ethan LazarusDenver$688K
- Michael de NardisLarkspur$335K
- Mark DeutchmanDenver$258K
- Kari UusinarkausWoodland Park$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.